share_log

MusclePharm (OTCMKTS:MSLP) Stock Crosses Below 200 Day Moving Average of $0.21

Defense World ·  Oct 6, 2022 03:11

MusclePharm Co. (OTCMKTS:MSLP – Get Rating)'s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.21 and traded as low as $0.13. MusclePharm shares last traded at $0.16, with a volume of 5,541 shares trading hands.

MusclePharm Trading Up 11.7 %

The stock has a 50-day moving average of $0.18 and a two-hundred day moving average of $0.21. The firm has a market cap of $5.26 million, a price-to-earnings ratio of -0.27 and a beta of 0.38.

MusclePharm Company Profile

(Get Rating)

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products.

Featured Stories

  • Get a free copy of the StockNews.com research report on MusclePharm (MSLP)
  • 3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
  • Don't Forget About These Cheap, Fundamentally Strong Tech Stocks
  • Bellwether RPM International Pops On Results
  • Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
  • Hot Potato: Lamb Weston Stock Confirms a Top

Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment